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prophylaxis cost far exceeding the direct ﬁnancial beneﬁt of preventing hospitaliza-
tions. Factors associated with lower ICERs included young age and the presence of 
multiple indications.
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OBJECTIVES: To develop a cost-effectiveness analysis of formoterol associated to 
budesonide for maintenance and reliever therapy (FB SMART) versus salmeterol 
associated do ﬂuticasone (SF) in the treatment of patients with moderate to severe 
persistent asthma, under the Brazilian societal perspective. METHODS: A Markov 
model was developed to project costs and outcomes associated with disease progres-
sion of patients with moderate to severe persistent asthma receiving SMART therapy 
or SF in a one year time horizon. Weekly cycles were considered and the model 
structure consisted of four possible health states: disease control, use of oral corticoids 
(OC), hospitalization/emergency visit (H/ER) and death. The probabilities of having 
severe exacerbations (OC or H/ER) were extracted from the study by Kuna et al. All 
cause mortality rates were obtained from national epidemiological databases. Adverse 
events were not signiﬁcantly different between comparators so were excluded from 
the model. Outcomes were expressed as severe exacerbations avoided (SEA) and only 
direct medical costs were included in the analysis. Resource use during hospitalization 
was estimated based on an expert panel. Maximum prices to consumer were obtained 
for drugs, and procedure costs were extracted from the Brazilian Classiﬁcation of 
Medical Procedures (CBHPM). RESULTS: In one year, the average number of severe 
exacerbations was 0.2436 in the SMART group and 0.3928 in the SF group, resulting 
in 0.1492 severe exacerbations avoided. Total cost for the SMART and SF groups 
were R$1823.56 and R$1417.49, respectively (incremental cost  R$406.07). The 
incremental cost-effectiveness ratio in 1 year was R$2721/SEA (US$1944 2005-PPP-
index USD1.0  R$1.4). The variables that most inﬂuenced the results were the costs 
of SMART and SF therapy and the cost of hospitalization. CONCLUSIONS: SMART 
therapy reduces the risk of severe exacerbations when compared to SF in patients with 
moderate to severe persistent asthma, at a reasonable incremental cost, being a valu-
able alternative for these patients.
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OBJECTIVES: Currently, no smoking cessation product is listed on National Essential 
List of Essential Medicine in Thailand. This study aimed to evaluate the cost-effective-
ness of non-nicotine smoking cessation products in Thailand from health care system 
perspective. METHODS: A Markov model was used to simulate the effects of 
smoking-cessation on cohorts of 10,000 male smokers age 40 who regularly smoked 
10–20 cigarettes a day. An incremental cost-effectiveness ratio of varenicline, bupro-
pion, and nortriptyline compared to self-quitting was estimated. Transition probabili-
ties were obtained from literature reviews, while medical care costs and utilization 
patterns were derived from a database of a Thai tertiary-care hospital and from 
the literature. The efﬁcacy of all three products was obtained from a Bayesian meta-
analysis. Costs of the medications were obtained from the Thai Drug and Medical 
Supply Information Center. Both costs and outcome were discounted at three percent. 
All costs were presented in 2008 Thai Baht. A series of sensitivity analysis including 
probabilistic sensitivity analysis, and cost-effectiveness acceptability curve were per-
formed. RESULTS: In comparison to self-quitting, using a non-nicotine smoking ces-
sation product results in cost-savings. Varenicline use results in the highest cost savings 
of 21,187 Baht or approximately US$605 and life-years gain of 0.25 years. The use 
of nortriptyline and bupropion was shown to lead to similar magnitude of both life 
years saved and cost-savings. Nortriptyline and bupropion use had cost-savings of 
11,506 Baht and 10,734 Baht, respectively. Probabilistic sensitivity analyses demon-
strate that the probability of cost-saving from using nortriptyline, varinicline, and 
bupropion for smoking cessation were 99%, 85%, and 80%, respectively. CONCLU-
SIONS: From the perspective of the health care system, using of any of the three 
products yielded cost-savings and life-year gains. These ﬁndings may persuade Thai 
policy-makers to consider including these smoking cessation products on the National 
List of Essential Medicine.
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OBJECTIVES: To evaluate the economic impact of the Non-Smokers Health Protec-
tion Act, implemented sApril 3rd, 2008 in terms of direct employment, wages, income 
and expenses in restaurants, bars and night clubs, in Mexico City. METHODS: 
The main information source is the Monthly Services Survey, produced by Nacional 
Institute of Statistics and Geography. The monthly series begins in January 2005 
and the last available observation is for March 2009. Natural logarithms of the 
dependent variables were constructed and differences-in-differences models were 
estimated by Ordinary Least Squares (OLS) to evaluate the impact using a control 
group conformed by Nuevo León and Jalisco, states that had similar behaviour 
before the date of implementation. RESULTS: Differences-in-differences estimations 
with robust p-values in parenthesis for the effect of implementation in restaurants are 
0.144 (0.57) for direct employment; 0.78 (0.568) for wages; 0.050 (0.277) for 
income and 0.174 (0.09) for expenses. In the case of bars and night clubs: 0.004 
(.976), 0.019 (0.883), 0.025 (0.56) and 0.049 (0.552) for direct employment, wages, 
income and expenses, respectively. Coefﬁcients are non signiﬁcant statistically. CON-
CLUSIONS: With available data, we conclude that there is no statistical evidence at 
95% conﬁdence level that suggests that the implementation of the Mexico City’s 
Non-Smokers Health Protection Act has had a negative economic effect in direct 
employment, wages, income and expenses in restaurants, bars and night clubs in 
Mexico City.
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OBJECTIVES: To assess, in real life conditions, the costs, effects, and cost-effective-
ness of Xolair® (omalizumab) as add-on versus conventional therapy in the manage-
ment of Belgian patients with severe persistent allergic asthma inadequately controlled. 
METHODS: The same Markov model used for omalizumab initial reimbursement 
dossier was populated with data from a Belgian observational study, i.e. PERSIST 
study (n  160), especially set up to address questions raised by the Belgian authorities 
for omalizumab re-evaluation. The model takes into account four health states and 
links effectiveness data, real life resource use, and utility data. Medical resources use 
(drug treatment, laboratory tests and procedures, physician consultations, emergency 
room visits, and hospitalisations) were collected in PERSIST and costed from the 
perspective of the health care payer (i.e. INAMI/RIZIV  patient). EQ-5D data were 
also collected during the study and used in the Markov model. RESULTS: Over a 
lifelong time horizon, the expected average numbers of life years (LYs) and QALYs 
per patient, for conventional therapy are 18.33 and 9.80, respectively. For omali-
zumab, the respective ﬁgures are 22.19 and 12.54. Over a lifelong time horizon, the 
expected average costs per patient are a44,548 and a124,726 for conventional therapy 
and omalizumab as add-on, respectively. Hence, omalizumab ICERs are a20,777/LY 
gained and a29,187/QALY gained. This compares very favourably (cf. substantial 
decrease in the ICERs) with the initial submission ICERs (i.e. a40,370/LY gained and 
a42,669/QALY gained). The sensitivity analyses performed show that results can 
somewhat vary according to the parameters changed. However, in all cases, the ICERs 
obtained with real life data are always markedly inferior to what was calculated in 
our initial submission. CONCLUSIONS: The pharmacoeconomic evaluation based on     
data from a real life Belgian study conﬁrms that omalizumab is cost-effective versus 
conventional therapy in the treatment of patients with severe persistent allergic asthma 
inadequately controlled.
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OBJECTIVES: The aim of this study is to analyze if tiotropium bromide is an efﬁcient 
alternative respect to ipratropium bromide and standard therapy, in the management 
of chronic obstructive pulmonary disease (COPD) patients in Spain. METHODS: 
Efﬁciency of the different alternative options in COPD treatment was evaluated with 
a cost-effectiveness analysis. Tiotropium bromide was compared to ipratropium 
bromide and standard therapy by means of a cost-effectiveness analysis that estimates 
life years gained (LYG) with tiotropium respect to alternatives, by combining mortality 
associated to COPD exacerbations with rates of exacerbations taken from two 
meta-analysis of head to head clinical trials. The time horizon of the study was 13 
years, the mean life expectancy in COPD patients included in the clinical trials 
with tiotropium. Uncertainty was studied by successive univariant sensitivity 
analysis of key parameters of the model and a probabilistic sensitivity analysis. 
All costs were expressed in a2008 and a 3% discount rate was applied to costs and 
effects. The analysis took the perspective of the Spanish National Health System 
(NHS). RESULTS: Incremental cost-effectiveness ratio (ICER) when treating COPD 
patients with tiotropium versus standard therapy was a2873/LYG, and in patients 
treated with tiotropium versus ipratropium bromide was a4208/LYG. Univariant 
sensitivity analysis showed that results where most sensitive to COPD severity and the 
future costs of surviving patients. CONCLUSIONS: Treating COPD patients with 
tiotropium is an efﬁcient alternative respect ipratropium bromide or standard therapy 
for the Spanish NHS.
